Form 4: Bausch & Lomb EVP of R&D and CMO, Yehia Hashad, Reports Stock and Option Grants

Yehia Hashad, EVP of R&D and CMO at Bausch & Lomb, reports the acquisition of restricted stock units and stock options.

Summary

• Yehia Hashad, EVP of R&D and CMO of Bausch & Lomb Corporation, filed a Form 4 on February 28, 2025.
• The report details changes in beneficial ownership due to the grant of restricted stock units (RSUs) and stock options.
• Hashad acquired 25,225 common shares through RSUs, which vest in equal installments over three years from the grant date of February 26, 2025.
• He also acquired options to purchase 60,085 common shares at an exercise price of $15.86, vesting in equal installments over three years and expiring ten years from the grant date.
• Following these transactions, Hashad directly owns 119,580 common shares and options for 60,085 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of RSUs and stock options aligns Hashad's interests with those of the shareholders, incentivizing him to drive long-term value for Bausch & Lomb.
• The vesting schedule of the RSUs and stock options encourages continued service and commitment from Hashad.

Future Outlook

The vesting of RSUs and stock options is contingent upon continued service, suggesting an expectation of Hashad's ongoing role at Bausch & Lomb.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices for executives at Bausch & Lomb.

Stakeholder Impact

• Shareholders may view the grant of RSUs and stock options positively, as it incentivizes management to improve company performance.
• Employees may see this as a positive sign of investment in leadership.

Key Dates